Leucine-rich repeat and immunoglobulin-like domain (LRIG) 1 is a negative regulator of receptor tyrosine kinases and a tumor suppressor; decreased LRIG1 expression is consistently observed in various types of cancer and is linked to poor patient prognosis [152]. This evidence concerns the gene LRIG1 and cancer.